CClinicalTrials.gg
CompletedNCT04556370Updated Jun 13, 2023

Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia.

An interventional study of Normal saline and Norepinephrine in Adverse Effect, sponsored by General Hospital of Ningxia Medical University. Completed at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-06-13.

Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The purpose of this study is to investigate the suitable infusion dose of norepinephrine for prophylaxis against postspinal anesthesia hypotension in parturients with preeclampsia undergoing cesarean section.

Read the detailed description

Preeclampsia, which affects 5% to 7% of parturients, is a significant cause of maternal and neonatal morbidity and mortality. Because of constricted myometrial spiral arteries with exaggerated vasomotor responsiveness, though blood pressure in parturients with preeclampsia are apparently higher than healthy parturients, placental hypoperfusion is more common. Spinal anesthesia is still the preferred mode of anesthesia in parturients with preeclampsia for cesarean section. In preeclampsia parturients, spinal anesthesia improve intervillous blood flow (provided that hypotension is avoided) which contribute to increase placental perfusion. Even so, 17-26% parturients with preeclampsia experienced postspinal anesthesia hypotension due to the extensive sympathetic block that occurred with spinal anesthesia. As a potential substitute drug for phenylephrine and ephedrine, norepinephrine has gained traction for use in parturients undergoing cesarean section. But the suitable infusion dose of norepinephrine in parturients with preeclampsia is still unknown. The purpose of this study is to investigate the suitable infusion dose of norepinephrine for prophylaxis against post-spinal anesthesia hypotension in parturients with preeclampsia undergoing cesarean section.

02

Conditions studied

  • Adverse Effect

Keywords

  • Norepinephrine
  • Postspinal anesthesia hypotension
  • Preeclampsia
  • Cesarean section
  • Dose-finding
03

In context

Pre-Eclampsia

882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.

This study's enrollment of 180 is above the median of 110 across 468 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

General Hospital of Ningxia Medical University is the lead sponsor of 102 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • 18-45 years
  • Primipara or multipara
  • Singleton pregnancy ≥32 weeks
  • American Society of Anesthesiologists physical status classification II to III
  • Scheduled for cesarean section under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Baseline blood pressure ≥180 mmHg
  • Body height \< 150 cm
  • Body weight > 100 kg or body mass index (BMI) ≥ 40 kg/m2
  • Eclampsia or chronic hypertension
  • Hemoglobin \< 7g/dl
  • Fetal distress, or known fetal developmental anomaly
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
180 participants (actual)

Study arms

  • Placebo comparator
    Control group

    Normal saline infusion simultaneous with subarachnoid block

    Drug: Normal saline

  • Experimental
    0.025 μg/kg/min group

    A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block

    Drug: Norepinephrine

  • Experimental
    0.050 μg/kg/min group

    A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block

    Drug: Norepinephrine

  • Experimental
    0.075 μg/kg/min group

    A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block

    Drug: Norepinephrine

Interventions

  • DrugNormal saline

    Normal saline infusion simultaneous with subarachnoid block

    Also known as: NS

  • DrugNorepinephrine

    Different infusion dose of norepinephrine simultaneous with subarachnoid block

    Also known as: Vasopressors

06

What researchers measure

Primary outcomes

  1. The incidence of post-spinal anesthesia hypotension

    Systolic blood pressure (SBP) \< 80% of the baseline

    Time frame: 1-15 minutes after spinal anesthesia.

Secondary outcomes

  1. Overall stability of systolic blood pressure control versus baseline

    Evaluated by performance error (PE)

    Time frame: 1-15 minutes after spinal anesthesia

  2. Overall stability of heart rate control versus baseline

    Evaluated by performance error (PE)

    Time frame: 1-15 minutes after spinal anesthesia

  3. The incidence of severe post-spinal anesthesia hypotension

    Systolic blood pressure (SBP) \< 60% of the baseline

    Time frame: 1-15 minutes after spinal anesthesia

  4. The incidence of nausea and vomiting

    Presence of nausea and vomiting in patients after spinal anesthesia

    Time frame: 1-15 minutes after spinal anesthesia

  5. The incidence of bradycardia

    Heart rate \< 55 beats/min

    Time frame: 1-15 minutes after spinal anesthesia

  6. The incidence of hypertension.

    Systolic blood pressure (SBP) \>120% of the baseline.

    Time frame: 1-15 minutes after spinal anesthesia

  7. pH

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery

  8. Partial pressure of oxygen

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery

  9. Base excess

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery

  10. APGAR score

    A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration

    Time frame: 1 min after delivery

  11. APGAR score

    A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration

    Time frame: 5 min after delivery

07

Study locations

1 site
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 75004, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04556370
Lead sponsor
General Hospital of Ningxia Medical University
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Nov 16, 2021
Primary completion
Jun 6, 2023
Completion
Jun 6, 2023
Last update
Jun 13, 2023

Study contacts

Yi Chen, M.D.
study chair · General Hospital of Ningxia Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion